Schroder Investment Management Group Summit Therapeutics Inc. Transaction History
Schroder Investment Management Group
- $112 Billion
- Q2 2025
A detailed history of Schroder Investment Management Group transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Schroder Investment Management Group holds 144,507 shares of SMMT stock, worth $2.53 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
144,507
Previous 233,597
38.14%
Holding current value
$2.53 Million
Previous $4.51 Million
31.76%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
270Shares Held
90.5MCall Options Held
4.71MPut Options Held
3.17M-
Baker Bros. Advisors LP New York, NY33.7MShares$591 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.67MShares$152 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$138 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$70.4 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$68.4 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.53B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...